December 5, 2025 — The attention that goes daily to the subject of preserving muscle and its importance is off the chart. Just this week a call to action about muscle loss in diabetes and a new systematic review on the effects of resistance exercise on cognitive function are demanding our attention. It is clear that preserving muscle as […]
July 18, 2025 — Retatrutide is that impressively potent obesity medicine that teased us with remarkable weight loss outcomes back in 2023. As we wait for pivotal phase three data (now due later this year), we wonder about the risk for muscle loss with a drug that has the potency of retatrutide. A new paper in Lancet Diabetes & […]
June 5, 2025 — Regeneron announced tantalizing results for the combination of trevogrumab with semaglutide for losing fat while preserving muscle. With the combination of these two drugs, it appears that individuals might lose more fat mass and less muscle mass than with semaglutide alone. In short, the promise is for a better quality of weight loss, leaving people […]
October 12, 2024 — Amid a great deal of excitement about the value of GLP-1 medicines like semaglutide and tirzepatide for obesity, there is also a buzz of concern about muscle loss. Is it a reason to think twice about these new treatments? Or is it merely a reason for caution? Not Unique to GLP-1s Carla Prado, Stuart Phillips, […]
October 4, 2023 — People have “lots of interest” in the effects of GLP-1 treatment for obesity on body composition, reports endocrinologist Daniel Drucker from EASD in Hamburg. Judging from clickbait headlines about semaglutide, we suspect public interest in this question is strong as well. So that makes data presented at EASD from the SURPASS study on muscle composition […]
